Johnson & Johnson (NYSE:JNJ) is among the most profitable healthcare stocks to buy<\/strong>. On January 22, TD Cowen lifted the price target on Johnson & Johnson (NYSE:JNJ) to $250, up from $222, and maintained a Buy rating, citing the company\u2019s fourth quarter results. The revised price target reflects an upside potential of approximately 14%.<\/p>\n According to the firm, the initial projection of Johnson & Johnson (NYSE:JNJ) should uplift the consensus revenue and EPS forecasts for the healthcare powerhouse. From this year and beyond, the company\u2019s Pharmaceutical and Medical Devices franchises are expected to continue their growth trajectory, TD Cowen noted.<\/p>\n Trong Nguyen \/ Shutterstock.com<\/p>\n On the same day, several other analysts updated their outlooks to better reflect the company\u2019s Q4 performance, which exceeded market estimates with $24.6 billion in revenue. BofA Securities also slightly raised its price target on Johnson & Johnson (NYSE:JNJ) from $220 to $221 and reiterated a Neutral rating on the stock. The company\u2019s financial results were described as \u201csolid\u201d by the firm, which attributes it to the growth drivers, particularly currency movements.<\/p>\n \u200bJohnson & Johnson (NYSE:JNJ), headquartered in New Jersey, offers healthcare products worldwide. Founded in 1886, the company operates in two main segments: Innovative Medicine and MedTech.<\/p>\n While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/b>.<\/p>\n READ NEXT: <\/b>The Best and Worst Dow Stocks for the Next 12 Months<\/b> and <\/b>10 Unstoppable Stocks That Could Double Your Money<\/b>.<\/b><\/p>\n Disclosure: None.<\/p>\n<\/p><\/div>\n<\/div>\n<\/div>